3 Key Insights on US$ 60 Bn Opportunity in Global Immunoassays Market REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Driven by the increasing prevalence of chronic diseases and infectious diseases along with the outbreak of the COVID-19 pandemic, the Global Immunoassays Market is Forecasted to Cross US$ 60 Bn by 2028 says Ken Research Study. Immunoassays are bioanalytical techniques that use the precision of an antigen-antibody reaction to detect and quantify analytes in biological samples such as urine, blood, saliva, tissues, and cells. Such techniques are commonly used in clinical diagnostics, drug discovery, drug monitoring, and food testing. The proliferation of digital healthcare and smartphone/smart gadget-based immunoassays (IAs) readers have contributed to the development of futuristic IA formats for point-of-care testing (POCT) applications, including antigen and antibody testing, drug screens, and glucose testing. Such IA formats, along with digital healthcare capabilities, will witness a considerable rise in the forthcoming years that will reshape healthcare provision and clinical diagnostics. Present constraints in digital healthcare, including data security, and encryption will be acknowledged alongside the growing trend toward increased use of cloud computing. According to Ken Research estimates, the Global Immunoassay Market – which grew from around ~US$ 30 Bn in 2017 to nearly ~US$ 40 Bn in 2021 – is expected to grow further into a more than ~US$ 60 Bn opportunity by 2028. Ken Research shares 3 key insights on this high opportunity market from its latest Research Study. 1. Increasing Prevalence of Chronic and Infectious Diseases Worldwide is Driving the use of Immunoassays Techniques in Disease Diagnostics. The growing geriatric population worldwide, who are more exposed to chronic and infectious diseases, including arthritis, and dementia is propelling the Immunoassays market. In addition, the increasing prevalence of cancer, cardiovascular diseases, and autoimmune diseases, such as type 1 diabetes, and nephrological diseases is widening the use of immunoassay techniques in diagnostic testing. For instance, according to Scientific American, an American science magazine that covers science, health, and social justice issues, several autoimmune diseases affected nearly 4.5% of the world’s population in 2021. Download Free Sample Report @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz According to the World Health Organization (WHO), a United Nations agency responsible for global public health, nearly 18 million people die every year as a result of cardiovascular diseases. 2. The Infectious Diseases Segment Accounted for the Largest Share in the Immunoassays Market in 2021. The rising prevalence of infectious diseases, particularly since the Covid-19 pandemic, is driving up demand for Immunoassays testing for infectious diseases. The ongoing Covid-19 pandemic has disrupted more individuals’ livelihoods on a global scale, and it continues to be a source of concern and threat to people who are exposed to newly emerging and evolving infectious diseases. Aside from the Covid-19 pandemic, infectious diseases continue to be a major cause of death and suffering around the world. Diseases like malaria and dengue fever are yet expanding their global reach. Other diseases, such as common pneumonia, diphtheria, human immunodeficiency virus (HIV)/AIDS, influenza, and tuberculosis, are prevalent in almost every country. 3. North America has Seen Accelerated Growth in Immunoassays Market, Owing to the Increased Demand for Technologically Advanced Products. Increased demand for facile diagnostics in North America, notably in the U.S. has boosted the advancement of immunological diagnostics (IDx) that assess the presence of viral surface antigens using an antibody (virus IDx), as these tests produce faster results than molecular diagnostics (MDx). Furthermore, the Covid-19 outbreak, like other highly contagious infectious diseases, such as severe acute respiratory syndrome (SARS), and Ebola virus disease, prompted the rapid development and adoption of diagnostics in North America. For instance, according to the Multidisciplinary Digital Publishing Institute (MDPI), a Swiss publisher of open access scientific journals, the United States and China dominated the diagnostic market in 2020, accounting for 49.7% of diagnostics developed. In addition, the global development activity of molecular diagnostics (MDx) and immunological diagnostics (IDx) changed dramatically as the pandemic evolved. During the Recovery Phase, from August to October 2020, a higher proportion of IDx emerged, accounting for an average of 62.7% of diagnostic development. This upsurge in immune-based detection solution activities appears to correlate with disease severity and the inability of molecular-based diagnostics, such as RT-qPCR to detect recent infections. Some countries experienced such surges during the pandemic’s first wave, while others experienced them during the second wave, priorities shifted to continuous monitoring strategies to better understand the disease’s geographical spread and severity in the population. Furthermore, the large number of Covid-19 MDx and IDx technologies developed in the U.S. can be contributed to their larger market share and a large number of diagnostic companies based in North America, implying a greater opportunity for the development of solutions to diagnose the virus. For more information on the research report, refer to the below link: Rapid Chromatographic Immunoassay Test Market: Ken Research Contact Us: – Ken Research Ankur Gupta, Head Marketing & Communications support@kenresearch.com +91-9015378249 Tags: abbott immunoassays analyzer Market Share, Africa Immunoassays Market, AI Solution Providers for Antibody/Antigen Testing, Asia Pacific Immunoassays Market, Autoimmune Diseases Immunoassays Market, Beckman Coulter Immunoassay Analyzers Market, Cardiology Immunoassays Market, Clinical diagnostic tests Market, Competitors in immunoassay Sector, Emerging Companies in Immunoassays Market, Europe Immunoassays Market, Global Chemiluminescence Immunoassay Market, Global ELISA Market, Global Enzyme Immunoassays Market, Global Enzyme-Linked Immunosorbent Assays Market, Global Fluoro immunoassay Market, global immunoassay diagnostics market, Global Immunoassays Analyzers Market, Global Immunoassays Application, Global Immunoassays Industry, Global Immunoassays Instruments Market, Global Immunoassays Reagents Kits Market, Global Radio immunoassay Market, immunoassay consumables and equipment, Immunoassays Companies Worldwide, Immunoassays Company Profiles, Infectious Diseases Immunoassays Market, Key Competitors in Immunoassays Market, Laboratory Reagents Manufacturers and Suppliers, Latin America Immunoassays Market, Leading Immunoassay Laboratory, Leading Players in Immunoassays Market, Major Companies in Immunoassays Market, Manufacturer of Diagnostic Instruments, Middle East Immunoassays Market, North America Immunoassays Market, Oncology/Cancer Immunoassays Market, PerkinElmer Alpha Immunoassay Kits Market, Quidel Corp Immunoassays Instruments Market, Rapid Chromatographic Immunoassay Test Market, Siemens Healthineers Immunoassay Systems, Specimen Collection Devices Manufacturer, Sysmex Corp Automated Immunoassay System, Thermo Fisher Scientific Immunoassays, Top Companies in Immunoassays Market, Western Blotting Test Market, Worldwide Immunoassays Market